A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice

Nakamura,Ken; Fukunishi,Shinya; Yokohama,Keisuke; Ohama,Hideko; Tsuchimoto,Yusuke; Asai,Akira; Tsuda,Yasuhiro; Higuchi,Kazuhide

doi:10.3892/ijmm.2017.2899

A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice

Authors:
- Ken Nakamura
- Shinya Fukunishi
- Keisuke Yokohama
- Hideko Ohama
- Yusuke Tsuchimoto
- Akira Asai
- Yasuhiro Tsuda
- Kazuhide Higuchi
View Affiliations

Affiliations: Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
Published online on: February 20, 2017 https://doi.org/10.3892/ijmm.2017.2899
Pages: 969-983

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-alcoholic fatty liver disease (NAFLD) occurs in patients with components of metabolic syndrome such as type 2 diabetes mellitus (T2DM). At present, the central pathophysiological problem in patients afflicted with NAFLD is insulin resistance. In this study, we aimed to determine the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, teneligliptin, on the development of NAFLD in ob/ob mice. Five-week-old male ob/ob mice were divided into 4 experimental groups as follows: a group in which they were fed a high carbohydrate diet (HCD) for 8 weeks (n=8) as controls (control group 1), a group in which they were fed HCD supplemented with 0.018% teneligliptin for 8 weeks (n=8) (teneligliptin group 1), a group in which they were fed HCD for 12 weeks (n=8) as controls (control group 2), and another group in which they were fed only HCD for 4 weeks, and the HCD was then supplemented with 0.018% teneligliptin for 8 weeks (n=8) (teligliptin group 2). Hepatic steatosis was observed in all mice in the control group fed the HCD, but only mild hepatic steatosis was observed in teneligliptin group 1. Mice in teneligliptin group 1 fed the diet containing teneligliptin had lower hepatic triglyceride (TG) and free fatty acid (FFA) levels. Mice in teneligliptin group 1 exhibited improvement of insulin resistance; however, those in teneligliptin group 2 did not show any improvement of insulin resistance. Our results thus suggest that teneligliptin may be used as a preventative, but not as a treatment drug for the development of NAFLD.

View Figures

View References

1	Matsuzawa Y: The role of fat topology in the risk of disease. Int J Obes. 32(Suppl 7): S83–S92. 2008. View Article : Google Scholar
2	Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:434–438. 1980.PubMed/NCBI
3	Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW and Powell LW: The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 11:74–80. 1990. View Article : Google Scholar : PubMed/NCBI
4	Yoshiike N and Lwin H: Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res. 33:77–82. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ahrén B: Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 3:365–372. 2003. View Article : Google Scholar : PubMed/NCBI
6	Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 122:531–544. 2002. View Article : Google Scholar : PubMed/NCBI
7	Mentlein R, Gallwitz B and Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 214:829–835. 1993. View Article : Google Scholar : PubMed/NCBI
8	Deacon CF, Johnsen AH and Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 80:952–957. 1995.PubMed/NCBI
9	Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D and Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 89:2078–2084. 2004. View Article : Google Scholar : PubMed/NCBI
10	Pratley RE and Salsali A: Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 23:919–931. 2007. View Article : Google Scholar : PubMed/NCBI
11	Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA and Camilleri M: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 56:1475–1480. 2007. View Article : Google Scholar : PubMed/NCBI
12	Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR and Gagliardino JJ: Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond). 120:73–80. 2011. View Article : Google Scholar
13	Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, et al: Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 20:5705–5719. 2012. View Article : Google Scholar : PubMed/NCBI
14	Friedman JM, Leibel RL, Siegel DS, Walsh J and Bahary N: Molecular mapping of the mouse ob mutation. Genomics. 11:1054–1062. 1991. View Article : Google Scholar : PubMed/NCBI
15	Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
16	Tomas E, Wood JA, Stanojevic V and Habener JF: Glucagon-like peptide-1 (9–36) amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induce obese.
17	Gao B: Innate immunity and steatohepatitis: A critical role of another toll (TLR-9). Gastroenterology. 139:27–30. 2010. View Article : Google Scholar : PubMed/NCBI
18	Dentin R, Girard J and Postic C: Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): Two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie. 87:81–86. 2005. View Article : Google Scholar : PubMed/NCBI
19	Foretz M, Guichard C, Ferré P and Foufelle F: Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA. 96:12737–12742. 1999. View Article : Google Scholar : PubMed/NCBI
20	Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, Le Lièpvre X, Berthelier-Lubrano C, Spiegelman B, Kim JB, Ferré P and Foufelle F: ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol. 19:3760–3768. 1999. View Article : Google Scholar : PubMed/NCBI
21	Cohen P and Friedman JM: Leptin and the control of metabolism: Role for stearoyl-CoA desaturase-1 (SCD-1). J Nutr. 134:2455S–2463S. 2004.PubMed/NCBI
22	Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S and Cusi K: Pioglitazone in the treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther. 32:769–775. 2010. View Article : Google Scholar : PubMed/NCBI
23	Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 405:421–424. 2000. View Article : Google Scholar : PubMed/NCBI
24	Knopp RH: Drug treatment of lipid disorders. N Engl J Med. 341:498–511. 1999. View Article : Google Scholar : PubMed/NCBI
25	Postic C and Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest. 118:829–838. 2008. View Article : Google Scholar : PubMed/NCBI
26	Srere PA: The citrate cleavage enzyme. I Distribution and purification. J Biol Chem. 234:2544–2547. 1959.PubMed/NCBI
27	Abu-Elheiga L, Jayakumar A, Baldini A, Chirala SS and Wakil SJ: Human acetyl-CoA carboxylase: Characterization, molecular cloning, and evidence for two isoforms. Proc Natl Acad Sci USA. 92:4011–4015. 1995. View Article : Google Scholar : PubMed/NCBI
28	van der Leij FR, Kram AM, Bartelds B, Roelofsen H, Smid GB, Takens J, Zammit VA and Kuipers JR: Cytological evidence that the C-terminus of carnitine palmitoyltransferase I is on the cytosolic face of the mitochondrial outer membrane. Biochem J. 341:777–784. 1999. View Article : Google Scholar : PubMed/NCBI
29	Park EA, Mynatt RL, Cook GA and Kashfi K: Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA abundance of hepatic carnitine palmitoyltransferase-I. Biochem J. 310:853–858. 1995. View Article : Google Scholar : PubMed/NCBI
30	Bartlett K and Eaton S: Mitochondrial beta-oxidation. Eur J Biochem. 271:462–469. 2004. View Article : Google Scholar : PubMed/NCBI
31	Hegarty BD, Turner N, Cooney GJ and Kraegen EW: Insulin resistance and fuel homeostasis: The role of AMP-activated protein kinase. Acta Physiol (Oxf). 196:129–145. 2009. View Article : Google Scholar
32	Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
33	Kubota N, Kubota T, Itoh S, Kumagai H, Kozono H, Takamoto I, Mineyama T, Ogata H, Tokuyama K, Ohsugi M, et al: Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 8:49–64. 2008. View Article : Google Scholar : PubMed/NCBI
34	Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV and White MF: The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol. 29:5070–5083. 2009. View Article : Google Scholar : PubMed/NCBI
35	Cernea S and Raz I: Therapy in the early stage: Incretins. Diabetes Care. 34(Suppl 2): S264–S271. 2011. View Article : Google Scholar : PubMed/NCBI
36	Valera A, Pujol A, Pelegrin M and Bosch F: Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 91:9151–9154. 1994. View Article : Google Scholar : PubMed/NCBI